Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 811 results for "gilead sciences"

The Most Important Number in Gilead Sciences' Earnings Report

This earnings season, there's no doubt that Gilead Sciences ( NASDAQ:GILD ) is one of the top-notch stocks to own in the healthcare market. With guidance being increased not once but two times this year, investors are excited to see that the ... Motley Fool, 9 hours ago
Motley Fool

5 Can't-Miss Quotes From Gilead Sciences Management

Image source: Gilead Sciences. Investors are correct to be giddy about Gilead Sciences ' ( NASDAQ:GILD ) second-quarter sales growth and its impact on the company's financials, but second-quarter sales aren't the only things that Gilead Sciences ...
 Motley Fool1 day ago
Benzinga.com

Thursday's Vital Data: Facebook Inc (FB), Pfizer Inc. (PFE) and Gilead Sciences, Inc. (GILD)

Popular Posts: Recent Posts: Stocks extended their gains on Wednesday, as Wall Street found strength ahead of the release of key U.S. economic reports. Due out this morning are data on U.S. second-quarter GDP and weekly jobless claims. For ...
 InvestorPlace.com3 days ago Gilead Sciences: Here's What A Bull And A Bear Are Saying  Benzinga.com4 days ago Gilead Sciences Q2 Profit Tops Estimates; Updates Full Year Guidance  RTTNews.com5 days ago Earnings Whispers: Yelp Inc (YELP), Gilead Sciences, Inc. (GILD) Quarterly Earnings Result  Bidness Etc5 days ago
[x]  
Pharma Letter

Gilead Sciences announces positive data from Phase III HIV infection study

Gilead Sciences, Inc., a biopharmaceutical company, has announced positive 48-week data from an open-label Phase III study, evaluating its investigational once-daily single tablet regimen, or STR, of elvitegravir 150mg, cobicistat 150mg, ...
 Individual.com4 days ago Traders Alert: Gilead Sciences, ( GILD), Host Hotels and Resorts (HST), Seadrill (SDRL), Kinder Morgan (KMI)  Techsonian3 days ago Gilead's product sales soar due to Harvoni  Orthopedics Today3 days ago Gilead Sciences, Inc. Continue To Surge On Q215 Results  Bidness Etc4 days ago
[x]  
FOXBusiness.com

Gilead 2Q Profit Beats, 2015 Sales Outlook Raised

Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates. Looking ahead, Gilead raised its outlook for full-year 2015 product sales by $1 billion to between ...
 FOXBusiness.com5 days ago UPDATE 1-Gilead Q2 profit beats Wall Street, 2015 sales outlook raised  CNBC5 days ago Gilead hepatitis C sales beat Wall Street, sales outlook raised  Yahoo! Finance5 days ago Gilead 2nd-quarter profit increases 32 pct, 2015 outlook raised  Reuters5 days ago
[x]  
TheStreet.com

Cramer -- Gilead Has a Fabulous Quarter, Tons of Merger Opportunities

Reddit Email Print Reprint NEW YORK ( TheStreet ) -- It's a goodday to be an investor in biotech Gilead Sciences ( GILD - Get Report ) . Shares are up over 4% Wednesday, a day after the company topped earnings per share and revenue estimates ...
 TheStreet.com4 days ago Gilead Sciences (GILD) Stock Climbing in After Hours Trading Following Earnings Results  TheStreet.com5 days ago 'Fast Money' Recap: Goodbye, July; Will August Be More of the Same?  TheStreet.com1 day ago

Gilead Sciences Rises 2.33% on Heavy Volume: Watch For Potential Pullback

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $115.11 to a high of $119.46. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $117.15 on volume of 23.0 million shares. ...
 Individual.com4 days ago Watch for Gilead Sciences to Potentially Rebound After Falling 4.11% Yesterday  Individual.com1 week ago SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 4.11% Loss  Comtex SmarTrend1 week ago

Lowest Future Earnings Growth in the Biotechnology Industry Detected in Shares of Gilead Sciences (GILD, AMGN, BIIB, MYGN, REGN)

(Comtex SmarTrend(R)) Below are the three companies in the Biotechnology industry with the lowest future earnings growth. The growth of earnings per share (next fiscal year estimated vs. current fiscal year estimated) is important to gauge future ...
 Individual.com2 days ago Lowest EV/EBITDA Ratio in the Biotechnology Industry Detected for Gilead Sciences (GILD, MYGN, AMGN)  Individual.com1 week ago Top 5 Companies in the Biotechnology Industry With the Highest Projected Earnings Growth (LGND, GILD, CELG, RGEN, EBS)  Comtex SmarTrend1 day ago

JPMorgan Chase & Co. Reaffirms Overweight Rating for Gilead Sciences (GILD)

JPMorgan Chase & Co. reiterated their overweight rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report report published onWednesday, MarketBeat reports. In other Gilead Sciences news, Director John Francis Cogan sold 27,000 ...
 SleekMoney1 day ago Gilead Sciences Earns Outperform Rating from Robert W. Baird (GILD)  SleekMoney1 day ago Gilead Sciences Stock Rating Reaffirmed by Robert W. Baird (GILD)  WKRB News2 days ago Gilead Sciences's Overweight Rating Reaffirmed at Morgan Stanley (GILD)  WKRB News3 days ago
[x]  

Gilead Sciences, Inc. Rules 95% Of The HCV Market

Gilead Sciences, Inc. ( NASDAQ:GILD ) currently rules the US HCV market with around 95% market share, leaving its rival, AbbVie Inc ( NYSE:ABBV ), far behind in the race, according to Symphony Health Data used by Bloomberg Intelligence. ...
 Bidness Etc2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less